Zogenix, Inc. (ZGNX): Price and Financial Metrics
ZGNX Price/Volume Stats
| Current price | $26.68 | 52-week high | $26.90 |
| Prev. close | $26.26 | 52-week low | $11.03 |
| Day low | $26.51 | Volume | 11,252,300 |
| Day high | $26.90 | Avg. volume | 3,764,363 |
| 50-day MA | $22.56 | Dividend yield | N/A |
| 200-day MA | $17.33 | Market Cap | 1.50B |
ZGNX Stock Price Chart Interactive Chart >
Zogenix, Inc. (ZGNX) Company Bio
Zogenix develops and commercializes therapies for the treatment of central nervous system disorders. The company was founded in 2006 and is based in San Diego, California.
Latest ZGNX News From Around the Web
Below are the latest news stories about Zogenix Inc that investors may wish to consider to help them evaluate ZGNX as an investment opportunity.
Analysts Estimate Envestnet (ENV) to Report a Decline in Earnings: What to Look Out forZogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial DiseasesSymptoms of mitochondrial diseases, such as Thymidine Kinase 2 deficiency (TK2d), can vary widely and mimic other rare and common diseases, making diagnosis challenging 1,2,3Genetic testing offers a quicker, confirmatory path to diagnosis, enabling more accurate care and participation in available clinical trials 1,2,3An estimated 1 in 5,000 individuals has a genetic mitochondrial disease 4 EMERYVILLE, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical c |
Why Zogenix Flew Higher Before Leveling Off This WeekZogenix (NASDAQ: ZGNX) stock is having the ride of its life this week -- perhaps for the last time in its history. The biotech announced Wednesday it agreed to be acquired by Belgium-based pharmaceutical company UCB (OTC: UCBJF). The company's share price quickly rocketed higher, but it's basically stayed at the enhanced level. |
Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & MoreRegulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week. |
ZGNX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 40.27% |
| 5-year | -30.30% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -18.71% |
| 2020 | -61.65% |
| 2019 | 42.98% |
Continue Researching ZGNX
Want to see what other sources are saying about Zogenix Inc's financials and stock price? Try the links below:Zogenix Inc (ZGNX) Stock Price | Nasdaq
Zogenix Inc (ZGNX) Stock Quote, History and News - Yahoo Finance
Zogenix Inc (ZGNX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...